Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients

Annals of Oncology

Volumn 17, Issue 1, 2006, Pages 74-78

  Del Mastro, Lucia ^a   Catzeddu, T ^a   Boni, L ^a   Bell, C ^a,b   Sertoli, M R ^a,c   Bighin, C ^a   Clavarezza, M ^a   Testa, D ^a   Venturini, M ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b STANFORD CANCER INSTITUTE   (United States)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Breast cancer; Early menopause; Fertility preservation

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; FOLLITROPIN; GOSERELIN; TAMOXIFEN;

ADULT; AGE; ARTICLE; BONE DISEASE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; EARLY CANCER; FEMALE; FOLLITROPIN BLOOD LEVEL; HEADACHE; HOT FLUSH; HUMAN; MASTECTOMY; MENOPAUSAL SYNDROME; MENSTRUAL CYCLE; MOOD DISORDER; OVARY FUNCTION; OVARY INSUFFICIENCY; PHASE 2 CLINICAL TRIAL; PREMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SWEATING; VAGINAL DRYNESS;

EID: 29844441294     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj029     Document Type: Article

References (31)

1. Hankey BF, Miller B, Curtis R, Kosary C. Trends in breast cancer in younger women in contrast to older women. Monogr Natl Cancer Inst 1994; 16: 7-14.
2. Goldhirsch A, Glick JH, Gelber RD Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19: 3817-3827.
3. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14: 1718-1729.
4. Del Mastro L, Venturini M, Sertoli MR et al. Phase III adjuvant trial comparing standard versus accelerated FEC regimen in early breast cancer patients. Results from GONO-MIG1 study. Breast Cancer Res Treat 2003; 82 (Suppl 1): S9 (Abstr).
5. Levine MN, Bramwell VH, Pritchard KI et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 1998; 16: 2651-2658.
6. Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: Prognostic role and clinical implications. Breast Cancer Res Treat 1997; 43: 183-190.
7. Partridge AH, Gelber S, Peppercorn J et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004; 22: 4174-4183.
8. Radford JA, Lieberman BA, Brison DR et al. Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma. Lancet 2001; 357: 1172-1175.
9. Oktay K, Buyuk E, Veeck L et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; 363: 837-840.
10. Karashima T, Zalatnai A, Schally AV. Protective effects of analogs of luteinizing hormone-releasing hormone against chemotherapy-induced testicular damage in rats. Proc Natl Acad Sci USA 1988; 85: 2329-2333.
11. Rivkees AS, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. J Am Med Assoc 1988; 259: 2123-2125.
12. Ataya KM, McKanna JA, Weintraub AM et al. A luteinizing hormone-releasing hormone Agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Research 1985; 45: 3651-3656.
13. Bokser L, Szende B, Schally AV. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer 1990; 61: 861-865.
14. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995; 52: 365-372.
15. Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr 2005; 34: 40-43.
16. Braverman AS, Sawhney H, Tendler A et al. Pre-menopausal serum estradiol (E2) levels may persist after chemotherapy (CT)-induced amenorrhea in breast cancer (BC). Proc Am Soc Clin Oncol 2092; 21: 42a (Abstr 164).
17. Ravdin PM, Fritz NF, Tormey DC, Jordan CV. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 1988; 48: 1026-1029.
18. Klijn JGM, Louk VA, Beex AM et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study. J Natl Cancer Inst 2000; 92: 903-911.
19. Fallace WH, Anderson R, Baird D. Preservation of fertility in young women treated for cancer. Lancet Oncol 2004; 5: 269-270.
20. Donnez J, Dolmans MM, Demylle D et al. Live birth after orthotropic transplantation of cryopreserved ovarian tissue. Lancet 2004; 364: 1405-1410.
21. Oktay K, Tilly J. Live birth after cryopreserved ovarian tissue autotransplantation. Lancet 2004; 364: 2091-2092.
22. Oktay K, Buyuk E, Libertella N et al. Fertility preservation in breast cancer patients: A prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 23: 4347-4353.
23. Partridge AH, Winer EP. Fertility after breast cancer: Questions abound. J Clin Oncol 23: 4259-4261.
24. The International Breast Cancer Study Group. Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients. Ann Oncol 1990; 1: 30-35.
25. Rivkin SE, Green S, O'Sullivan J et al. Adjuvant CMFVP versus adjuvant CMFYP plus ovariectomy for premenopausal, node positive, and estrogen receptor-positive breast cancer patients. A Southwest Oncology Group Study. J Clin Oncol 1996; 14: 46-51.
26. Arriagada R, Le MG, Spielmann M et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol 2005; 16: 389-396.
27. Early Breast Cancer Trialists' Collaborative Group. Ovarian Ablation for Early Breast Cancer (Cochrane Review). The Cochrane Library, issue 3. Chichester, UK: John Wiley Ltd. 2004.
28. Jonat W, Kaufmann M, Sauerbrei W et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002; 20: 4628-4635.
29. Fox KR, Scialla J, Moore H. Preventing chemotherapy-related amonorrhea using leuprolide during adjuvant chemotherapy for early-stage breast cancer. Proc Am Soc Clin Oncol 2003; 22: 13 (Abstr 50).
30. Recchia F, Sica G, De Filippis S et al. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: A phase II pilot study. Anticancer Dugs 2002; 13: 417-424.
31. Urriticoechea A, Walsh G, Rigg A et al. Ovarian function protection with goserelin during adjuvant chemotherapy in pre-menopausal women with early breast cancer. Breast Cancer Res Treat 2004; 88 (Suppl 1): S229 (Abstr 6028).